http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
건강 비만성인에 있어서의 시판 다이어트 제품의 다이어트효과와 안전성에 대한 연구
신현택,권혁명,김수빈,강신욱,여익현,Shin, Hyun-Taek,Kweon, Hyuk-Myung,Kim, Soo-Bin,Kwang, Sin-Uk,Yu, Ik-Hyun 한국임상약학회 1995 한국임상약학회지 Vol.5 No.2
Obesity is defined as excessive storage of energy in the form of fat resulting in adverse effect on healthy and longevity. Some data have shown increased incidence of hypertension, diabetes, hypercholesterolemia in overweight individuals and other disorders such as joint disease, cancer have been also associated with obesity. Recently, various commercial diet programs have been introduced for weight reduction without scientific evaluation for clinical effect and safety. The diet program must be based on a sound and scientific rationale and also be safe and nutritionally adequate. Pulmuone $diet^{(R)}$ is a calorie-restricted commercial diet-food, which contains adequate nutritients. The efficacy and safety of Pulmuone diet were evaluated in 28 normal healthy obese females in a prospective study. Each volunteer was placed in 3-week diet program. To observe weight reduction effect, body weight, TSF and AMC were measured every week. To account for safety of this program, blood chemistry test, blood pressure and side effects were monitored every week. Mean body weight was reduced by 3.24kg following diet program, which is statistically significant(P < 0.05) and this weight reduction was related to reduction in fat weight and not muscle weight as shown by the results of TSF and AMC Blood chemistry was not influenced by this program, but blood pressure was significantly reduced following this program. Thought diet program was generally well tolerated in most volunteers, the most frequent side effects are constipation, dizzness and headache. In conclusion, Pulmuone $diet^{(R)}$ program seems to be safe and effective for weight reduction in normal healthy obese females.
정신신경용계 의약품의 치료군 중복처방 평가기준(안) 개발
손현순(Hyun Soon Sohn),최윤영(Yoon Young Choi),이영숙(Young Sook Lee),최경업(Kyung Eob Choi),신현택(Hyun Taek Shin) 대한약학회 2011 약학회지 Vol.55 No.3
Therapeutic duplication (TD) is frequently reported inappropriate drug use in healthcare settings in Korea. This study was aimed to develop TD criteria for psycho-nervous system drugs (KFDA classification 117 and 119). ATC classification was used to determine therapeutic and/or chemical similarities among the 93 ingredients reviewed. Clinical practice guidelines, textbooks and product labels were referenced for principles and evidences of possible drug combination usage. 16 groups that listed ingredients to be considered as TD were established and the criteria would be helpful to prevent TDs.
의약품 부작용에 관한 국제 분류체계인 WHO-ART와 MedDRA의 비교분석
임경화,신현택,손현순,전효정,이주현,이유정,이영숙,송인숙,Lim, Kyung-Hwa,Shin, Hyun-Taek,Sohn, Hyun-Soon,Jun, Hyo-Jung,Lee, Joo-Hyun,Lee, Yoo-Jung,Lee, Young-Sook,Song, In-Sook 한국임상약학회 2007 한국임상약학회지 Vol.17 No.1
This study was aimed to provide the controlled terminology for adverse drug reactions by selecting an appropriate internationally standardized classifications (WHO-ART or MedDRA). We collected the relevant information on ADR terminology systems including WHO-ART and MedDRA by online searching and visiting pharmaceutical companies and WHO UMC (Uppsala Monitoring Centre, Uppsala, Sweden). For MedDRA, project leader directly communicated with the officer of MSSO (Maintenance and Support Services Organization). Collecting all the pertinent information, two possible terminology classifications or systems (WHO-ART and MedDRA) were compared in the views of acceptability, cost-effectiveness and international feasibility and reviewed by the consultation committee and finally WHO-ART was selected.
노인환자에게 제공하는 개국약국 약료서비스의 경제적 가치
손현순,신현택,Sohn, Hyun-Soon,Shin, Hyun-Taek 대한약학회 2007 약학회지 Vol.51 No.5
This study was to evaluate economic impact of a comprehensive pharmaceutical care intervention provided by community pharmacists on drug-related morbidity and mortality in the elderly population, in a societal perspective. Clinical outcomes of pharmaceutical care included compliance increase, inappropriate medication discontinuation, and subsequent drug-related morbidity and mortality reduction. Economic outcomes included cost savings from direct medical costs reduction such as medication and healthcare resource utilization. Input costs for pharmaceutical care included pharmacist time and computerized prescription review supporting program costs. Model parameters of outcomes were derived from published literatures, and costs were from literatures and health insurance statistical data in Korea. Annual costs and benefits were estimated in the year 2005. Current usual care and standardized pharmaceutical care required 0.3 and 2.0 hours per year respectively, for elderly outpatient using average 4.4 prescription drugs per visit and average annual frequency of 17.8 pharmacy visits. Comprehensive pharmaceutical care provided to overall elderly outpatients at community pharmacies would have cost of \74,994 mil. and benefit of \357,002 mil. per year. Benefit:cost ratio was 4.8:1 and net benefit was \282,008 mil/year. It was corresponded to net benefit of \73,816/year for individual elderly patient. In addition, pharmaceutical care was estimated to reduce 1,531 drug-related deaths/year. Conclusively this study, a first attempt in Korea to evaluate an economic value of pharmaceutical care at community pharmacies, proved that it was a cost-effective intervention having significant economic benefit.
소용량 Vancomycin 주사액 조제방법의 차이에 의한 정확성 비교: 단일희석방법과 이중희석방법
신혜영,서옥경,이숙향,신현택,Shin, Hea Young,Suh, Ok Kyung,Lee, Suk Hyang,Shin, Hyun Taek 한국임상약학회 1997 한국임상약학회지 Vol.7 No.2
This study was to find a more accurate method fur measuring small vancomycin dosages which are commonly used in neonates by comparing single and double dilution method. For single dilution method, 500 mg of vancomycin powder was accurately measured and reconstituted with 5 ml of distilled water to make a concentration of 100 mg/ml. Volumes of 0.05, 0.1, 0.15, 0.2, 0.3, 0.4, and 0.5 ml, which equal the target dosages of 5, 10, 15, 20, 30, 40, and 50 mg, were measured using syringes made by Shina and each sample was further diluted with 2 ml of $5\%$ dextrose. The solution of 100 mg/ml concentration was further diluted with $5\%$ dextrose to make a concentration of 20 mg/ml. Volumes of 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, and 2.5 ml, which correspond to 5, 10, 15, 20, 30, 40, and 50 mg, were sampled by the same Shina's syringe as in single dilution method and then each sample was further diluted to make a total volume of 10 ml. Each sample was analyzed by HPLC. The measured dosages of each sample in both single and double dilution methods were lower than the target dosages; however, e values in double dilution method were higher than those in single dilution method for seven target dosages. Percent target dosages in single dilution method were 65 to $90\%$, while in double dilution method 91 to $94\%$. Statistically significant difference between two groups was shown in 5, 10, 15, 20, and 40 mg dosages (p<0.05). In conclusion, when preparing small vancomycin dosages lower an 20 mg $(volume{\leq}0.2\;ml)$, using Shina's syringes, the double dilution method has a closer value to the target dosage than single dilution method.
이상지혈증을 동반한 제2형 당뇨병환자에서 미세화된 fenofibrate 제제와 서방형 fenoflbrate제제의 효능비교 연구
신화연(Hwa Yun Shin),오정미(Jung Mi Oh),강문호(Moon Ho Kang),신현택(Hyun Taek Shin) 대한약학회 2001 약학회지 Vol.45 No.5
Fenofibrate is a fibric acid derivative that is a strong reducer of triglyceride. Micronized formulation of fenofibrate has improved bioavailability compared to non- micrornized formulation. This study performed a retrospective comparison of micronized and non-micronized fenofibrate (28 in micronized and 51 in non-micronized group) by comparing the means of changes in total triglyceride, total cholesterol, HDL- cholesterol and TC/HDL ratio in type 2 diabetics with dyslipidemia. The result showed that after 12 weeks of treatment both drugs produced a significant reduction in total triglyceride levels (62% with micronized, 37% with non-micronized). The mean decrease observed for total triglyceride levels were signnificantly lower for micronized fenofibrate (p<0.001). Both drugs showed a significant reduction for total cholesterol levels (-22% with micronized, -14% with non-micronized fenofibrate). The mean decrease observed for total cholesterol was not significantly different between the two drugs (p>0.05). HDL-cholesterol levels increased by 24% and 15% with micronized and non- micronized, respectively and the differences from the baseline were statistically significant for both drugs (p<0.05). The mean change of HDL-cholesterol was not significantly different between the two drugs. There was a statistically significant reduction in TC/HDL-cholesterol ratio from baseline for both drugs (7.1 to 4.8 with micronized and 5.1 to 4.5 with non-micronized), and the reduction of TC/HDl.- cholesterol ratio tended to be significantly greater with micronized fenofibrate (p<0.05). This study shows that short-term treatment with microni3ed fenofibrate is more effective than non-micronized fenofibrate in type 2 diabetes patients with dyslipidemia.
최경업(Kyung Eob Choi),손현순(Hyun Soon Sohn),김남효(Nam Hyo Kim),신현택(Hyun Taek Shin),이영숙(Young Sook Lee) 대한약학회 2012 약학회지 Vol.56 No.2
Purpose: To develop therapeutic duplication criteria for the drugs used for respiratory diseases. Method: Therapeutic duplication was defined as "more than 2 drug ingredient-usage in which each has the same therapeutic effect and combination therapy does not confer additional therapeutic benefit". Respiratory system drugs approved in Korea were examined for the study. The WHO’s Anatomical Therapeutic Chemical Classification System was used for grouping of the corresponding drug ingredients. The principles and recommendations on combination usage or multiple drug regimens were reviewed by using the clinical practice guidelines, textbooks, product labelings, and clinical articles. Clinical expert group consultation was performed and expert opinions were incorporated into the final criteria. Results: Nine hundred sixty two drug products with Korean Food and Drug Administration classification codes of 141, 149, 222, and 229 were evaluated, of which 87 active ingredients were composed. The drug ingredients were classified into 12 groups (antihistamines, oral nasal decongestants, leukotriene receptor antagonists, inhaled anticholinergics, inhaled corticosteroids, oral β2-agonists, long-acting β2-agonists, short-acting β2-agonists, xanthines, antiallergics, mucolytics and cough suppressants). The use of more than 2 drug ingredients including the same group was therapeutic duplication, and thus combination should be recommended not to be used. Conclusion: Twelve drug groups were identified as therapeutic duplication criteria. Combination therapy within each group should not be used otherwise therapeutic benefits outweigh potential risks.